Clinical Trial

Xerostomia-optimised IMRT Versus Standard IMRT in NPC

Recruiting
View on ClinicalTrials.gov →
Summary
This is a multi-center, non-inferiority, open-label, randomized controlled phase III clinical trial in primary diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis. This study aims to compare the regional control, survival outcomes, radiation-related toxicities, and quality of life (QoL) of xerostomia-optimized intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in NPC patients
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-21.
Trial Details
NCT Number NCT06282497
Lead Sponsor Zhongshan People's Hospital, Guangdong, China
Conditions Nasopharyngeal Carcinoma ,Xerostomia,Radiotherapy
Enrollment 524 participants
Start Date 2023-10-23
Primary Completion 2026-10-23 (estimated)
Study Completion 2029-10-23 (estimated)
Updated on ClinicalTrials.gov 2024-05-01